Double blind, randomised, multicentre, phase II/III study of nintedanib with Pemetrexed/Cisplatin followed by nintedanib monotherapy Vs placebo with Pemetrexed/Cisplatin followed by placebo monotherapy for treatment of unresectable malignant pleural mesothelioma